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Abstract 
Background: The aim of the present study was to determine the maternal pre-pregnancy body mass index (BMI), 
first-trimester fasting blood sugar (FBS), and the combination of (BMI+FBS) cut-points for at-risk pregnant women 
conceived by assisted reproductive technology (ART) to better predict the risk of developing gestational diabetes mel-
litus (GDM) in infertile women. 
Materials and Methods: In this nested case-control study, 270 singleton pregnant women consisted of 135 (GDM) 
and 135 (non-GDM) who conceived using ART were assessed. The diagnosis of GDM was confirmed by a one-step 
glucose tolerance test (O-GTT) using 75 g oral glucose. BMI was classified base on World Health Organization 
(WHO) criteria. The relationship between BMI, FBS, and BMI+FBS with the risk of GDM development was deter-
mined by logistic regression and adjusted for confounding factors. Receiver operating characteristic (ROC) curve 
analysis was performed to assess the value of BMI, FBS, and BMI+FBS for the prediction of GDM.  
Results: The GDM group had significantly higher age, BMI, family history of diabetes, and history of polycystic ovary syn-
drome in comparison with the non-GDM group (P<0.05). Overweight and obese women had 3.27, and 5.14 folds increase 
in the odds of developing GDM, respectively. There was a 17% increase in the risk of developing GDM with each 1 mg/dl 
increase in fasting glucose level. The cut points for FBS 84.5 mg/dl (72.9% sensitivity, 74.4% specificity), BMI 25.4 kg/m2 
(68.9% sensitivity, 62.8% specificity), and BMI+FBS 111.2 (70.7% sensitivity, 80.6% specificity) was determined. 
Conclusion: The early screening and high-quality prenatal care should be recommended upon the co-occurrence of 
high FBS (≥84.5 mg/dl) in the first-trimester of the pregnancy and the BMI (≥25.4 kg/m2) in pre-pregnancy period in 
women undergone ART. The combination of BMI and FBS is considered a better prediction value.
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Introduction 
Gestational diabetes mellitus (GDM) is one of the main 
obstetrics complications among pregnant women with a 
history of fertility problem (1), particularly in mothers re-
ceiving infertility treatment by assisted reproductive tech-
nology (ART) (2). Recent studies reported the association 
between ART treatment and GDM risk (3). Moreover, 
pregnancies complicated with GDM can result in adverse 
maternal and perinatal consequences (4). Genetic predis-
position, ethnicity, and age are the most significant risk 
factors for GDM; furthermore, maternal obesity is con-
sistently proposed as a major and modifiable risk factor 
(5). Along with obesity accretion rate, there is an increase 
in the number of obese infertile women seeking infertility 
treatments through ART (6). 
In general terms, GDM is detected at mid-pregnancy 
(24th-28th weeks of gestation) by oral glucose tolerance test 
(OGTT). Nevertheless, there is evidence suggesting that 
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GDM occurs in all trimesters of pregnancy (7). However, 
high-risk mothers are assessed in the first-trimester for hy-
perglycemia in pregnancy. Lately, several studies proposed 
evaluating the first-trimester prediction of GDM based on 
maternal characteristics (8). Previously, researchers found 
that body mass index (BMI) (9) and fasting blood sugar 
(FBS) level (10, 11) were independent predictors of GDM 
in normal pregnancy and pregnancies in women with a 
prior history of polycystic ovary syndrome (PCOS) (12). 
Recent investigation showed that age, BMI and mode of 
ART were independent risk factors for GDM in patients 
undergoing ART (13). 
The national institute for health and care excellence 
(NICE) guidelines (2013) recommended determining the 
cut-off points for BMI among different populations to help 
prevent diabetes and the other chronic conditions (14). Fur-
thermore, BMI cut-off as an indicator of GDM was diverse 
in compliance with race and ethnicity (15). Recent system-
atic review and meta-analysis evaluated the predictive ac-
curacy of the different combination of GDM risk factors in 
high-risk women in spontaneous pregnancy (16). 
However, there is no consensus about GDM diagnosis 
regarding screening time, method and, the optimal cut 
points. Also, there is no direct evidence concerning the 
cut-off levels for pre-pregnancy BMI and fasting glucose 
to predict the risk of developing GDM in infertile women 
as a high-risk population. Accordingly, the present study 
was designed to evaluate the predictive values of maternal 
BMI and FBS to predict GDM risk, and then to determine 
the cut-points for BMI, FBS, and the combination of two 
biomarkers (BMI+FBS) for the diagnosis of at-risk preg-
nant women conceived using ART to target clinical sur-
veillance in a more effective manner.
Materials and Methods
This nested case-control study was conducted between 
October 2016 and June 2017. The data from 270 women 
with singleton pregnancies (135 GDM and 135 non-GDM 
women) conceived by ART treatment referred to Royan 
Institute were studied. ART was defined as being con-
ceived by intracytoplasmic sperm injection (ICSI) and/
or in vitro fertilization (IVF). Prior to data collection, the 
protocol of the study was approved by the institutional 
review board and Ethics Committee of Iran University 
of Medical Science (Project number: 25469). Clinical 
records of the participants were reviewed. Consent form 
was obtained and completed by participants. Data on ma-
ternal history and demographic characteristics as well as 
the records of the first-trimester para-clinical evaluations 
were collected from the documents. The target population 
was defined as women with singleton pregnancy via ART 
and aged between 20-42 years. The exclusion criteria 
were pre-gestational diabetes; chronic diseases (consisted 
of hypertension, cardiovascular diseases, untreated thy-
roid disease, liver diseases, renal diseases, autoimmune 
diseases, and connective tissue disorders); corticosteroids 
usage, and incomplete records. Pre-gestational diabetes 
was defined when the first-trimester FBS was above 125 
mg/dl. GDM was confirmed by an OGTT using 75 g oral 
glucose at the first-trimester (for high-risk subjects) or 
24-28 weeks of gestation (for non-GDM subjects). The 
results of OGTT were interpreted by American diabetes 
association (ADA) criteria (17). The diagnosis of ges-
tational diabetes was based on FBS ≥92 mg/dl, 1 hour 
OGTT ≥180 mg/dl mg/dl, and 2 hour OGTT ≥153 mg/dl. 
Women with high-risk GDM were screened by OGTT on 
their first antenatal visit. High-risk subjects were defined 
as individuals with a history of GDM, obesity, impaired 
glucose metabolism, and history of PCOS. Non-GDM 
women were screened by OGTT at the 24th to 28th weeks 
of gestation. Women who had normal OGTT at the 24th to 
28th weeks of pregnancy were considered the non-GDM 
(control) group and individuals with abnormal OGTT 
were considered the GDM group.
The data pertaining to the characteristics of patients and 
infertility treatment cycle were collected as previously 
described in details (18). Pre-pregnancy weight (weight)
and height were measured before the initiation of ART cy-
cles by trained nurses. BMI was calculated as the weight 
in kilograms was divided by the square of height in me-
ters. According to world health organization (WHO), di-
agnostic criteria (19) women were categorized as normal 
weight (BMI <25 kg/m2), overweight (BMI 25.0 -29.9 kg/
m2), and obese (BMI≥30.0 kg/m2).
Statistical analysis  
Data were analyzed using the statistical package for 
the social sciences (SPSS) software for Windows (ver-
sion 20, Chicago, IL, USA). Descriptive data were pre-
sented as the mean ± standard deviation (SD) or number 
(%) where appropriate. The independent sample t test 
was used to compare quantitative data with normal dis-
tribution between the two groups. Chi-square test was 
applied to compare the qualitative variables. The logis-
tic regression analysis was performed to calculate the 
relationship between BMI, FBS, and BMI+FBS with the 
risk of GDM after ART cycles. The result of the analysis 
was expressed as odds ratio (OR) and 95% confidence 
intervals (CIs). ORs were presented either as crude or 
adjusted values for confounding variables (age, gravid-
ity, PCOS diagnosis, and family history of diabetes). 
The patients with BMI<25 kg/m2 were considered the 
reference group. The Hosmer-Lemeshow test was used 
for the goodness of fit in logistic regression models and 
the Pearson's chi-square was calculated. The Nagelkerke 
Pseudo-R2 was determined to quantify predictive ability 
or model performance.
The receiver operating characteristic (ROC) curve anal-
ysis was done by MedCalc statistical software to measure 
the diagnostic accuracy of BMI, FBS, and BMI+FBS, as 
well as the optimal cut-point value as predictors for GDM. 
The DeLong method was used to compare the area under 
individual and paired ROC curves (AUC). Youden’s in-
dex and associated cut-off points were used to measure 
the overall diagnostic effectiveness. The level of signifi-
cance was set at P<0.05.
BMI and FBS Cut-off Points in GDM-ART
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Results
The clinical and biochemical baseline characteristics of 
participants are presented in Table 1. The mean maternal 
age was significantly higher in the GDM group (32.15 ± 
5.07 vs. 30.28 ± 4.89, P=0.003). There were significant 
differences in terms of gravidity, pre-pregnancy weight, 
BMI, history of diabetes in first relative degree, FBS, and 
PCOS diagnosis between the two groups (P<0.001 for all 
variables). There were no significant differences between 
the two groups in terms of parity, systolic and diastolic 
blood pressure, maternal education and infertility cause. 
The incidence of overweight (48.9 vs. 32.5%) and obe-
sity (23.7 vs. 10.9%) was significantly higher in the GDM 
group (P<0.001).
Table 1: Clinical and biochemical baseline characteristics of women conceived via ART with and without GDM
P valueGDM group
n=135  
Non-GDM group  
n=135 
Variable
0.00332.15 ± 5.0730.28 ± 4.89Maternal age  (Y)
0.00179 (58.5)100 (74.0)Gravidity (=1, primigravida) 
0.184114 (84.4)116 (85.9)Parity (=0, nulliparous)
<0.00169.77 ± 10.4564.34 ± 10.18Weight (kg)

















Maternal education     
Lower secondary     
Upper secondary
<0.00190.66 ± 10.2480.81 ± 5.45FBS (mg/dl)
<0.00135 (25.9)11 (8.1)PCOS diagnosis
0.078106.26 ± 9.77104.26 ± 8.50Systolic blood pressure (mmHg)










Infertility cause   
Ovulatory factor   
Male factor   
Tubal factor   
Unexplained
Data are presented as mean ± SD or n (%). ART; Assisted reproductive technology, GDM; Gestational diabetes mellitus, BMI; Body mass index, FBS; Fasting blood sugar, and PCOS; 
Polycystic ovary syndrome.




























Nagelkerke R² 0.118 0.126 0.119 0.116











FBS (mg/dl) 1.171 (1.12-1.20) 1.56 (1.28-1.90) 1.71 (1.41-2.07) 1.4 (1.26-1.56)
Nagelkerke R² 0.364 0.400 0.429 0.422











BMI; Body mass index, FBS; Fasting blood sugar, CI; Confidence interval, GDM; Gestational diabetes mellitus, OR; Odds ratio, and PCOS; Polycystic ovary syndrome. Data are presented 
as OR (95% CI), Model 1; Adjusted by age and gravidity, Model 2; Adjusted by age, gravidity and PCOS diagnosis, Model 3; Adjusted by age, gravidity, PCOS diagnosis and family history 
of diabetes, and *; The P value is related to the Hosmer and Lemeshow test- which is not significant- it shows goodness of fitting the model. 
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Logistic regression analysis illustrated that both FBS 
level and BMI were significant and independent risk fac-
tors for development of GDM after adjustment for con-
founding variables (age, gravidity, PCOS and family his-
tory of diabetes). The results of logistic regression showed 
that overweight and obese women had a 3.27-fold [ad-
justed OR (a-OR) 3.27, 95% CI,  (1.61, 6.66), P<0.002] 
and 5.14-fold [aOR 5.14, 95% CI, (1.53, 17.26), P<0.002] 
higher odds for GDM than that of normal weight women, 
respectively. There was an approximately 17% increase 
in the odds of developing GDM with each 1 mg/dl in-
crease in FBS level [OR 1.17, 95% CI, 1.17 (1.12-1.20), 
P<0.001] (Table 2). 
Our result presents that Nagelkerke Pseudo-R2 are 0.118 
(BMI) and 0.364 (FBS). It means that our model is stable 
and can predict the results. The Chi-square of Hosmer-
Lemeshow test is the interpreter the goodness of fit test 
for logistic regression and shows this model is fit for our 
data.
The ROC curves illustrate the ability of FBS, BMI, 
and BMI+FBS to predict GDM development (Fig.1). 
The ROC curve analysis showed the predictive values of 
0.69, 0.79, and 0.83 for BMI, FBS, and BMI+FBS, re-
spectively. 
Fig.1: Receiver operating characteristics (ROC) curve analysis for the abil-
ity of the first-trimester fasting blood sugar (FBS), pre-pregnancy body 
mass index (BMI), and BMI+FBS to predict gestational diabetes mellitus 
(GDM) in women conceived via assisted reproductive technology (ART). 
 
The values of BMI, FBS, and BMI+FBS for the predic-
tion of GDM and overall diagnostic effectiveness of each 
factor were presented in Table 3. On the basis of the ROC 
curves, the best cut-off point for FBS was 84.5 mg/dl, with 
a sensitivity of 72.9% (95% CI: 64.5-80.3) and specificity 
of 74.4% (95% CI: 66.0-81.7). Regarding BMI, the best 
cut-off point was obtained as 25.4 kg/m2 with a sensitiv-
ity of 68.9% (95% CI: 60.4-76.6), specificity of 62.8% 
(95% CI: 53.8-71.1). The combination of two biomarkers 
(BMI+FBS) has a better AUC value (0.83). The best cut-
off point for BMI+FBS was 111.2 with a sensitivity of 
70.7% (95% CI: 62.2-78.2) and specificity of 80.6% (95% 
CI: 72.7-87.0), separately. 
Table 3: The values of BMI, FBS and BMI+FBS for the prediction of GDM 
and their overall diagnostic effectiveness
ROC index BMI FBS BMI+FBS
AUC 0.69 0.79 0.83
95% CI of AUC 0.63-0.76 0.74-0.85 0.78-0.88
P value* <0.0001 <0.0001 <0.0001
Youden index J 0.304 0.473 0.513
Cut-off criterion 25.4 84.5 111.2
Sensitivity (%) 68.8 72.9 70.7
95% CI of sensitivity 60.4-76.6 64.5-80.3 62.2-78.2
Specificity 62.79 74.42 80.62
95% CI of specificity 53.8-71.1 66.0-81.7 72.7-87.0
Positive likelihood ratio 1.85 2.85 3.65
Negative likelihood ratio 0.5 0.36 0.36
BMI; Body mass index, FBS; Fasting blood sugar, GDM; Gestational diabetes mellitus, 
ROC; Receiver operating characteristic, AUC; Under individual ROC curves, CI; Confi-
dence interval, and *; P< 0.05 was significant.
The AUC of three ROC curves is compared in Table 4. 
The results indicate that there are significant differences 
among pairwise groups. The combination of BMI+FBS 
significantly improves the predictive ability of FBS or 
BMI alone for GDM development.
Table 4: The pairwise comparison of the area under the ROC curves be-
tween BMI, FBS, and BMI+FBS






Difference between areas 0.09 0.13 0.03
Standard error 0.041 0.031 0.013
95% confidence interval 0.016-0.18 0.070-0.19 0.0069-0.060
z statistic 2.35 4.20 2.46
Significance level P=0.02* P<0.0001* P=0.01*
ROC; Receiver operating characteristic, BMI; Body mass index, FBS; Fasting blood sug-
ar, *; P<0.05 was significant.
Discussion
In the present study, the predictive values of first-tri-
mester FBS, pre-pregnancy BMI, and the combination of 
two biomarkers for the development of GDM in pregnant 
women after ART treatment were determined. The results 
of this study demonstrated that overweight and obese 
women had approximately 3 and 5 folds increase in the 
odds of developing GDM, respectively. The cut-off point 
of 84.5 mg/dl for FBS had a sensitivity of 72.9% and 
specificity 74.4%, while the cut-off point of 25.4 kg/m2 
for BMI had a sensitivity of 68.8% and specificity of 
62.8%. However, the combination of BMI and FBS signif-
icantly improves the predictive ability for GDM develop-
ment (BMI+FBS cut point: 111.2 with 70.7% sensitivity, 
80.6% specificity).
Current evidence indicates that obesity has a negative 
effect on female reproductive health including ovulatory 
dysfunction, infertility problems, and poorer outcomes 
BMI and FBS Cut-off Points in GDM-ART
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after infertility treatment. Moreover, obesity is associated 
with impaired ovarian responsiveness to IVF treatment, 
a lower rate of oocyte fertilization, poor embryo quality, 
and higher abortion rates (20). 
In our study, a higher incidence of overweight (48.9 
vs.32.5%) and obesity (23.7 vs.10.9%) was observed in 
GDM compared to that of the non-GDM group in the 
ART population. Provost et al. (21) reported a higher rate 
of overweight (22.9%) and obesity (17.8%) among wom-
en undergoing ART.
Our data show a significant association between BMI 
and GDM in the ART population. Overweight and obese 
women had approximately 3 and 5 folds increase in odds 
of GDM, compared with normal BMI women. Consistent 
with our findings, Torloni et al. (5), in a meta-analysis of 
70 studies, reported that the risk of developing GDM in 
overweight and obese women in natural pregnancy was 
almost 2 and 4 folds higher in comparison to normal-
weight women. Furthermore, they showed an approxi-
mately 0.92% increase in the risk of developing GDM 
with each 1 kg/m2 BMI increase in women with a BMI>25 
kg/m2, (95% CI: 0.73-1.10). Another study performed by 
Ogonowski et al. (22), showed that the risk for GDM is 
increased in parallel with rising in pre-pregnancy BMI 
not only in overweight but also in normal-weight wom-
en. BMI is a strong predictor for GDM requiring insulin 
therapy. A recent large population-based study revealed 
the association between BMI and diabetes in pregnancy 
among women of various ethnicities (23). Moreover, 
overweight women had a 2.37-fold and obese women had 
a 5.88-fold increase in the risk of diabetes in pregnancy. 
Similar to our results, Nishikawa et al. (23) showed that 
applying a BMI cut-off of 25 kg/m2 would identify 68% 
of South Asian women with diabetes in pregnancy.
Anyway, there is controversy on GDM definition, 
screening time and method, and threshold values. Previ-
ously, a risk factor for GDM was defined as obese women 
who have BMI above 30 kg/m2 (24). ADA indicates BMI 
25kg/m2 or less as the low-risk group (25). The present 
study concludes that women with BMI≥ 25.4 kg/m2 are at 
high risk of GDM development after ART.
Recently, Cai et al. (26) demonstrated that IVF pregnan-
cies are associated with a higher rate of GDM along with 
elevated fasting and 2-hour OGTT blood glucose levels in 
the late second-trimester, particularly in overweight and 
obese mothers; however, the first-trimester FBS was not 
measured. Previously, Szymanska et al. (27), in a retro-
spective study, compared 36 singleton pregnant women 
with GDM who have undergone IVF with 137 non-IVF 
women with GDM and reported higher levels of FBS in 
pregnant women with GDM undergone IVF. Similarly, 
we found that GDM women undergone ART had higher 
levels of FBS in the first-trimester of pregnancy com-
pared with the non-GDM subjects, but FBS levels were 
observed within the normal range (FBS <92 mg/dl). Con-
versely, Sacks et al. (28) found that the measurement of 
FBS at the first-prenatal visit is not an efficient method for 
screening of GDM in natural pregnancies because of poor 
specificity (high false positive rate). Our findings show 
an approximately 17% increase in the risk of developing 
GDM with each 1 mg/dl increase in FBS level. In addi-
tion, we found a cut-off point of 84.5 mg/dl for FBS with 
sensitivity 73% and specificity 74%. Riskin-Mashiah et 
al. (10) reported a cut-off point of 79 mg/dl for FBS using 
100 g OGTT with sensitivity 80% and specificity 53% 
for GDM diagnosis in natural pregnancies. In addition, 
they found that with each 5 mg/dl increase in fasting glu-
cose or 3.5 kg/m2 increase in BMI, the risk of developing 
GDM increases 1.5-fold among young fertile women. 
As there is controversy about GDM screening and diag-
nosis, recent studies focused on the first-trimester predic-
tion of GDM based on the maternal and clinical charac-
teristics  (8, 29, 30) or biomarkers (31) during the natural 
pregnancy. Hence, in order to predict GDM risk, it is sug-
gested considering multi-parametric models according to 
maternal clinical risk factors and biomarkers in the first-
trimester in pregnancy. Our results showed that the com-
bination of two biomarkers (BMI+FBS) had a cut-point 
of 111.2 with 70.7% sensitivity and 80.6% specificity to 
predict GDM development. Moreover, the combination of 
BMI+FBS significantly improved the predictive ability of 
FBS or BMI alone for GDM development. Similar to our 
data, Hao and Lin (30) in a retrospective study carried 
out on 820 Chinese pregnant women who naturally con-
ceived reported that appropriate fasting plasma glucose 
(FPG) cut-off value for predicting GDM was 4.6 mmol/L 
(82.8 mg/dl) with a sensitivity of 53.89% and specificity 
of 70.90%. The BMI cut-off value was 23.5 kg/m2 with 
a sensitivity of 48.50%  and specificity of 73.05%. They 
found that the combination of these two indices could oc-
cupy a larger area under the curve for GDM prediction. 
Therefore, high levels of FBS or BMI in the first-trimes-
ter, especially when combined with each other, should be 
noticed by health care providers to screen GDM in wom-
en who conceived using ART.
On the basis of the authors’ knowledge, this is the first 
report in ART subjects. The current research has some 
limitations. We did not evaluate infertility-related factors 
(hormonal and environmental factors), habits, physical 
activity, pre-pregnancy waist and hip circumferences, and 
the dietary regimen of the participants.
Conclusion
Pre-pregnancy BMI and the first-trimester FBS are in-
dependent predictors of GDM in pregnant women con-
ceived by ART. The co-occurrence of high FBS and obe-
sity increases the risk of GDM dramatically in pregnant 
women conceived by ART. 
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